i2E Supports Glioblastoma Project

i2E has invested $500,000 in the Glioblastoma Project of the Oklahoma Medical Research Foundation, through the Oklahoma Seed Capital Fund. The seed fund participated in an investment round of $1 million with co-investment from OMRF.

PRESS RELEASE

i2E, Inc., has invested $500,000 in the Glioblastoma Project of the Oklahoma Medical Research Foundation, through the Oklahoma Seed Capital Fund. The Seed Fund participated in an investment round of $1 million with co-investment from OMRF.

OMRF’s Glioblastoma Project was developed to explore a potential new therapeutic approach for the more than 176,000 people annually who develop brain tumors known as glioblastomas. OMRF scientists have discovered that a compound derived from work in its laboratories shows some effect in preventing the growth of certain deadly brain tumors in laboratory rodents. With the support of i2E, OMRF is working with the Food and Drug Administration to begin testing the compound in patients suffering from glioblastomas, a condition for which there currently is no effective treatment.

The Oklahoma Seed Capital Fund is a state-appropriated investment fund that provides concept, seed and start-up equity investments to the state’s high-growth businesses. It is managed by i2E through a collaboration with the Oklahoma Center for the Advancement of Science and Technology.

About the Oklahoma Medical Research Foundation: Founded in 1946, OMRF is one of the nation’s oldest and most respected nonprofit biomedical research institutes. Located in Oklahoma City, OMRF fosters a worldwide reputation for excellence by following an innovative cross-disciplinary approach to medical research.

About i2E, Inc.: With offices in Oklahoma City and Tulsa, OK, i2E is a not-for-profit corporation that provides an award-winning suite of venture advisory, access to capital and entrepreneurial development programs for Oklahoma’s high growth businesses.